Presence of Anti-drug Antibodies Does Not Reduce the Efficacy of an Oral Anti-TNF Antibody in a Murine IBD Model

被引：0
|
作者：
Bhol, Kailash [1 ]
Erlich, Emma [1 ]
Lemos, Brenda [1 ]
Tracey, Daniel [1 ]
Hartman, Deborah [1 ]
Fox, Barbara [1 ]
机构：
[1] Avaxia Biol Inc, Lexington, MA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2013年 / 108卷
关键词：
D O I：
10.14309/00000434-201310001-01810
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1810
引用
收藏
页码：S545 / S546
页数：2
相关论文
共 50 条
  • [1] LOW DRUG CONCENTRATIONS AND ANTI-DRUG ANTIBODY FORMATION TO THE PRIOR ANTI-TNF PREDISPOSES PATIENTS WITH INFLAMMATORY BOWEL DISEASE TO DEVELOP ANTI-DRUG ANTIBODIES TO THE SUBSEQUENT ANTI-TNF
    Cheifetz, Adam S.
    Abreu, Maria T.
    Flier, Sarah N.
    Papamichail, Konstantinos
    Rieder, Florian
    Silverberg, Mark S.
    Khanna, Reena
    Okada, Lauren
    Yang, Lei
    Jain, Anjali
    Vande Casteele, Niels
    GASTROENTEROLOGY, 2020, 158 (06) : S457 - S457
  • [2] ANTI-DRUG ANTIBODIES, DRUG LEVELS AND CLINICAL EFFICACY OF THE ANTI-TNF BIOLOGICS IN RHEUMATIC DISEASES
    Mok, C. C.
    van der Kleij, D.
    Wolbink, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 226 - 226
  • [3] Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
    C. C. Mok
    D. van der Kleij
    G. J. Wolbink
    Clinical Rheumatology, 2013, 32 : 1429 - 1435
  • [4] Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
    Mok, C. C.
    van der Kleij, D.
    Wolbink, G. J.
    CLINICAL RHEUMATOLOGY, 2013, 32 (10) : 1429 - 1435
  • [5] SWITCHING OUT OF CLASS OR TO ANOTHER ANTI-TNF AGENT IS THE BEST STRATEGY FOR CLINICAL EFFICACY AND TREATMENT PERSISTENCE IN IBD PATIENTS WITH ANTI-DRUG ANTIBODIES AGAINST ANTI-TNF
    Anjie, Suzanne I.
    Hanzel, Jurij
    Gecse, Krisztina B.
    D'Haens, Geert
    Brandse, Johannan F.
    GASTROENTEROLOGY, 2023, 164 (06) : S1120 - S1121
  • [6] INCREASED RISK OF ANTI-DRUG ANTIBODIES TO A SECOND ANTI-TNF IN PATIENTS WHO DEVELOPED ANTIBODIES TO THE FIRST ANTI-TNF
    Yanai, Henit A.
    Amir, Shira
    Avni-Biron, Irit
    Perets, Tsachi Tsadok
    Shamir, Raanan
    Dotan, Iris
    Assa, Amit
    GASTROENTEROLOGY, 2020, 158 (06) : S671 - S671
  • [7] Increased risk of anti-drug antibodies to a second anti-TNF in patients who developed antibodies to the first anti-TNF
    Yanai, H.
    Amir, S.
    Biron, I. Avni
    Perets, T. Tsadok
    Shamir, R.
    Dotan, I.
    Assa, A.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S439 - S439
  • [8] Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients
    Colman, Ruben J.
    Portocarrero-Castillo, Andrea
    Chona, Deepika
    Hellmann, Jennifer
    Minar, Phillip
    Rosen, Michael J.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (04) : 507 - 515
  • [9] ANTI-DRUG ANTIBODIES AS A PREDICTOR FOR THE DISCONTINUATION OF ANTI-TNF AGENTS IN PATIENTS WITH SPONDYLOARTHRTIS
    Kim, H. J.
    Hwang, J.
    Kim, I.
    Jeong, H.
    Lee, J.
    Jeon, C. H.
    Koh, E. -M.
    Cha, H. -S.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 717 - 718
  • [10] ANTI-DRUG ANTIBODIES: ASSAY PERFORMANCE IN PATIENTS TREATED WITH ANTI-TNF BIODRUGS
    Hock, B.
    O'donnell, J. L.
    Liu, J.
    Keating, P.
    Spellerberg, M.
    Stamp, L.
    Barclay, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1415 - 1415
12345